Pharmacies a Hot Target for Phishing, Vishing, and Other Cyberattacks
24-09-2026 18:54 via pharmacypracticenews.com

Pharmacies a Hot Target for Phishing, Vishing, and Other Cyberattacks

Originally published by our sister publication Specialty Pharmacy Continuumfigure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Studio KN – stock.adobe.comBy Karen BlumImagine this scenario: You c
Read more »

Pharmacy news



Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors
Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors
New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care
New Teva Resource Aims to Move LAIs Earlier in Schizophrenia Care
Specialty Pharmacy Teams Can Play Helpful Roles in Lupus Management
Specialty Pharmacy Teams Can Play Helpful Roles in Lupus Management
RFID Can Help Hospitals Control High-cost Medication Inventories
RFID Can Help Hospitals Control High-cost Medication Inventories
Quality Specialty Pharmacy Programs Need Data, Dedicated Staffs
Quality Specialty Pharmacy Programs Need Data, Dedicated Staffs
When Law Enforcement Comes Knocking, Be Prepared
When Law Enforcement Comes Knocking, Be Prepared
Cold Chain Shipping: Why Pharmacies Struggle and How to Strengthen Compliance
Cold Chain Shipping: Why Pharmacies Struggle and How to Strengthen Compliance
New URAC Accreditation Offers Path to AI Implementation With Oversight
New URAC Accreditation Offers Path to AI Implementation With Oversight
What to Know About Bixlenvo for HIV
What to Know About Bixlenvo for HIV
Monitor Nutrition and Muscle Loss in Patients on Incretin-Based Obesity Drugs
Monitor Nutrition and Muscle Loss in Patients on Incretin-Based Obesity Drugs
Jideytro Approved for Previously Treated ROS1-Positive NSCLC
Jideytro Approved for Previously Treated ROS1-Positive NSCLC
Are We Aiming at the Right End Points in Crohn’s Disease?
Are We Aiming at the Right End Points in Crohn’s Disease?
AI Tools Require Strong Governance and Rigorous Vetting
AI Tools Require Strong Governance and Rigorous Vetting
Oral Paclitaxel Provides Infusion-Free Alternative in MBC
Oral Paclitaxel Provides Infusion-Free Alternative in MBC
Desktop versie